Showing results (451-460 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|February 5, 2020
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension studyHeinz Gisslinger, Christoph Klade, Pencho Georgiev, et al.
The Lancet. Haematology|February 28, 2020
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell ProjectChristopher P Fox, Monica Civallero, Young-Hyeh Ko, et al.
The Lancet. Haematology|November 26, 2020
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label studyPaola Tacchetti, Lucia Pantani, Francesca Patriarca, et al.
The Lancet. Haematology|December 28, 2020
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trialMarco Ladetto, Sergio Cortelazzo, Simone Ferrero, et al.
The Lancet. Haematology|December 28, 2020
The role of PET in first-line treatment of Hodgkin lymphomaJudith Trotman, Sally F Barrington
The Lancet. Haematology|December 21, 2020
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance databasePierre-Marie Morice, Alexandra Leary, Charles Dolladille, et al.
The Lancet. Haematology|October 22, 2020
A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to riseJennifer K Lue, Owen A O'Connor
The Lancet. Haematology|October 13, 2022
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trialReuben Benjamin, Nitin Jain, Marcela V Maus, et al.
The Lancet. Haematology|January 21, 2021
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trialTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
The Lancet. Haematology|January 29, 2021
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trialAndrés J M Ferreri, Jeanette K Doorduijn, Alessandro Re, et al.
Pageof 73